English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 January 2021, 08:00 HKT/SGT
Share:
Shanghai Longyao Chief Scientist Professor Xuanming Yang published a research article on optimizing CAR-T cells function with independently expressed full-length OX40
The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors

HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.

LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.

For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308



Topic: Press release summary
Source:

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Central China New Life (9983.HK) Exploring Lower-Tier Markets  
June 20, 2021 17:00 HKT/SGT
Unscientific, Unrealistic and Imaginary Claims; a threat to peace in the South China Sea  
June 20, 2021 11:00 HKT/SGT
Grand Ming Group Holdings Limited Announces Annual Results for the Year Ended 31 March 2021  
June 19, 2021 16:00 HKT/SGT
Oscar De La Hoya, King Of Pay-Per-View To Return To The Ring on Triller  
June 19, 2021 10:00 HKT/SGT
DeFi Powerhouse Fantom's Native Token FTM Gets Listed on BitFinex and Gemini  
June 19, 2021 04:00 HKT/SGT
Leon Fuat Berhad Shareholders Pass Resolution to Acquire Factory for Rm28.0 Million  
June 18, 2021 18:00 HKT/SGT
IMC Ventures Partners with PIER71 to Invest and Nurture the Maritime and Supply Chain Ecosystem in Singapore  
June 18, 2021 17:36 HKT/SGT
Toyota Yaris WRC to face another 'new' challenge on Africa's return  
June 18, 2021 16:08 HKT/SGT
Hitachi to Donate to COVID-19 Relief Efforts in India and Other Countries  
June 18, 2021 15:19 HKT/SGT
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate  
June 18, 2021 14:02 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575